Analysts give thumbs up to new Lundbeck data and phase III plans

Analysts are backing Lundbeck’s phase III plans for Lu AF82422, which has the potential to slow the progression of multiple system atrophy, a disease that does not yet have an approved treatment.
Photo: Jens Dresling
Photo: Jens Dresling

Lundbeck is currently in a race against the clock to convince hard-pressed investors that the company is capable of bringing fresh new products to the shelves as the company is faced with patent expirations in the coming years, including Brintellix in 2027 and Rexulti in 2029.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading